文献速递肝病

限时进食在代谢功能障碍相关脂肪性肝病中的疗效与安全性

Efficacy and safety of time-restricted eating in metabolic dysfunction-associated steatotic liver disease.
PubMed 文献 · J Hepatol · 2025-06-19

这项16周随机对照试验将337例超重或肥胖的MASLD患者按1:1:1分为标准治疗组、热量限制组和限时进食组,限时进食组肝脏脂肪含量较标准治疗组显著下降(-25.8% vs 0.7%,p<0.001),与热量限制组(-24.7%)无显著差异,未报告严重不良事件。

要点

  • 限时进食16周使MASLD患者肝脏脂肪含量较标准治疗显著下降(-25.8% vs 0.7%,p<0.001)。
  • 限时进食与热量限制在肝脏脂肪下降方面无显著差异(-25.8% vs -24.7%,p>0.999)。
  • 限时进食组体重、腰围和体脂量下降优于标准治疗组,与热量限制组相当,未报告严重不良事件。

核心结论

  • 限时进食可有效降低MASLD患者的肝脏脂肪含量,在体重减轻、身体成分和代谢指标方面的获益与热量限制相当。
  • 限时进食可能作为MASLD管理的一种实用饮食策略,但需进一步长期研究。

研究设计与样本

  • 16周随机对照试验,将超重或肥胖的MASLD患者按1:1:1比例随机分为标准治疗组、热量限制组和限时进食组。
  • 337例参与者随机化,333例纳入全分析集(标准治疗组113例、热量限制组110例、限时进食组110例)。
  • 主要终点为使用MRI质子密度脂肪分数评估的肝脏脂肪变改善。

主要发现

  • 16周干预后,限时进食组肝脏脂肪变显著下降(-25.8%),标准治疗组为0.7%(p<0.001)。
  • 限时进食组与热量限制组肝脏脂肪变变化无显著差异(-25.8% vs -24.7%,p>0.999)。
  • 限时进食组体重、腰围和体脂量下降大于标准治疗组,而限时进食组与热量限制组之间变化相当。
  • 限时进食组与热量限制组的肝脏硬度、血糖稳态和睡眠质量相似。
  • 未报告严重不良事件。

临床怎么用

  • 作者认为限时进食可能作为MASLD管理的一种实用饮食策略,但需进一步长期研究。

局限性

  • 原文在结论中提出需进一步长期研究(warranting further long-term investigations)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Time-restricted eating (TRE) may improve weight loss, insulin resistance, and body composition, which are key factors in the pathophysiology of metabolic dysfunction-associated steatotic liver disease (MASLD). However, evidence on the efficacy of TRE in patients with MASLD is limited. This study aimed to evaluate the potential benefits of TRE in patients with overweight or obesity and MASLD. METHODS: In this 16-week randomized controlled trial, patients with overweight or obesity and MASLD were randomized into three groups in a 1:1:1 ratio: standard of care (SOC), calorie restriction (CR), and TRE. The primary endpoint was an improvement in hepatic steatosis, measured using MRI-proton density fat fraction. Changes in liver fibrosis, body composition, lipid profiles, glucose homeostasis, and sleep quality were also analyzed. RESULTS: Among the 337 participants randomized, 333 were included in the full analysis set (113 in SOC, 110 in CR, and 110 in TRE). After the 16-week intervention, hepatic steatosis significantly decreased in the TRE group (-25.8%) compared to the SOC group (0.7%, p <0.001), with no significant difference between TRE and CR (-24.7%, p >0.999). The TRE group also showed greater reductions in body weight, waist circumference, and body fat mass compared to the SOC group, while changes were comparable between TRE and CR. Liver stiffness, glucose homeostasis, and sleep quality were similar between the TRE and CR groups. No serious adverse events were reported. CONCLUSIONS: TRE effectively reduces hepatic steatosis in MASLD, with comparable benefits on weight loss, body composition, and metabolic parameters as CR. This approach may serve as a practical dietary strategy for MASLD management. ClinicalTrals.gov: NCT05579158. IMPACT AND IMPLICATIONS: The efficacy of time-restricted eating in managing metabolic dysfunction-associated steatotic liver disease (MASLD) remains uncertain despite its potential metabolic benefits. This 16-week randomized controlled trial compared the effects of time-restricted eating, calorie restriction, and standard of care on hepatic steatosis and metabolic outcomes in patients with MASLD. Time-restricted eating effectively reduces hepatic steatosis in MASLD, with comparable benefits on weight loss, body composition, and metabolic parameters as calorie restriction. Time-restricted eating may serve as a practical dietary strategy for MASLD management, warranting further long-term investigations.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Oh JH, Yoon EL, Park H, et al. Efficacy and safety of time-restricted eating in metabolic dysfunction-associated steatotic liver disease. J Hepatol. 2025. PMID: 40543603. doi:10.1016/j.jhep.2025.06.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。